GH Stock Overview
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally.
Guardant Health, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$53.83|
|52 Week High||US$121.26|
|52 Week Low||US$27.65|
|1 Month Change||7.53%|
|3 Month Change||23.29%|
|1 Year Change||-49.93%|
|3 Year Change||-16.76%|
|5 Year Change||n/a|
|Change since IPO||67.17%|
Recent News & Updates
Here's Why Guardant Health (NASDAQ:GH) Can Afford Some Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
|GH||US Healthcare||US Market|
Return vs Industry: GH underperformed the US Healthcare industry which returned 9.1% over the past year.
Return vs Market: GH underperformed the US Market which returned -21.5% over the past year.
|GH Average Weekly Movement||10.3%|
|Healthcare Industry Average Movement||8.0%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: GH is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: GH's weekly volatility (10%) has been stable over the past year.
About the Company
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials.
Guardant Health, Inc. Fundamentals Summary
|GH fundamental statistics|
Is GH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|GH income statement (TTM)|
|Cost of Revenue||US$132.95m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-5.39|
|Net Profit Margin||-135.03%|
How did GH perform over the long term?See historical performance and comparison